Literature DB >> 33498737

Pure Ductal Carcinoma In Situ of the Breast: Analysis of 270 Consecutive Patients Treated in a 9-Year Period.

Corrado Chiappa1, Alice Bonetti1, Giulio Jad Jaber1, Valentina De Berardinis1, Veronica Bianchi1, Francesca Rovera1.   

Abstract

INTRODUCTION: Ductal carcinoma in situ (DCIS) is an intraductal neoplastic proliferation of epithelial cells that are confined within the basement membrane of the breast ductal system. This retrospective observational analysis aims at reviewing the issues of this histological type of cancer.
MATERIALS AND METHODS: Patients treated for DCIS between 1 January 2009 and 31 December 2018 were identified from a retrospective database. The patients were divided into two groups of 5 years each, the first group including patients treated from 2009 to 2013, and the second group including patients treated from 2014 to 2018. Once the database was completed, we performed a statistical analysis to see if there were significant differences among the 2 periods. Statistical analyses were performed using GraphPad Prism software for Windows, and the level of significance was set at p < 0.05.
RESULTS: 3586 female patients were treated for breast cancer over the 9-year study period (1469 patients from 2009 to 2013 and 2117 from 2014 to 2018), of which 270 (7.53%) had pure DCIS in the final pathology. The median age of diagnosis was 59-year-old (range 36-86). In the first period, 81 (5.5%) women out of 1469 had DCIS in the final pathology, in the second, 189 (8.9%) out of 2117 had DCIS in the final pathology with a statistically significant increase (p = 0.0001). From 2009 to 2013, only 38 (46.9%) were in stage 0 (correct DCIS diagnosis) while in the second period, 125 (66.1%) were included in this stage. The number of patients included in clinical stage 0 increased significantly (p = 0.004). In the first period, 48 (59.3%) specimen margins were at a greater or equal distance than 2 mm (negative margins), between 2014 and 2018; 137 (72.5%) had negative margins. Between 2014 and 2018 the number of DCIS patients with positive margins decreased significantly (p = 0.02) compared to the first period examined. The mastectomies number increased significantly (p = 0.008) between the 2 periods, while the sentinel lymph node biopsy (SLNB) numbers had no differences (p = 0.29). For both periods analysed all the 253 patients who underwent the follow up are currently living and free of disease. We have conventionally excluded the 17 patients whose data were lost.
Conclusion: The choice of the newest imaging techniques and the most suitable biopsy method allows a better pre-operative diagnosis of the DCIS. Surgical treatment must be targeted to the patient and a multidisciplinary approach discussed in the Breast Unit centres.

Entities:  

Keywords:  DCIS; breast cancer; ductal carcinoma; surgery

Year:  2021        PMID: 33498737      PMCID: PMC7865419          DOI: 10.3390/cancers13030431

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  76 in total

1.  The management of ductal carcinoma in situ of the breast: a screened population-based analysis.

Authors:  Eileen Rakovitch; Jean-Philippe Pignol; Carole Chartier; Wedad Hanna; Hariette Kahn; John Wong; Verna Mai; Lawrence Paszat
Journal:  Breast Cancer Res Treat       Date:  2006-07-13       Impact factor: 4.872

2.  Is there a role for MRI in the preoperative assessment of patients with DCIS?

Authors:  Lisa R Allen; Claudia E Lago-Toro; Jenevieve H Hughes; Eduardo Careaga; Anjeanette T Brown; Michael Chernick; Andrea V Barrio; Thomas G Frazier
Journal:  Ann Surg Oncol       Date:  2010-03-09       Impact factor: 5.344

3.  Diagnostic upgrade of atypical ductal hyperplasia of the breast based on evaluation of histopathological features and calcification on core needle biopsy.

Authors:  Lin-Ying Chen; Jintao Hu; Julia Y S Tsang; Michelle A Lee; Yun-Bi Ni; Siu-Ki Chan; Gary M K Tse
Journal:  Histopathology       Date:  2019-07-16       Impact factor: 5.087

4.  In situ and minimally invasive breast cancer: morphologic and kinetic features on contrast-enhanced MR imaging.

Authors:  P Viehweg; D Lampe; J Buchmann; S H Heywang-Köbrunner
Journal:  MAGMA       Date:  2000-12       Impact factor: 2.310

5.  Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ.

Authors:  Gary Tozbikian; Edi Brogi; Christina E Vallejo; Dilip Giri; Melissa Murray; Jeffrey Catalano; Cristina Olcese; Kimberly J Van Zee; Hannah Yong Wen
Journal:  Int J Surg Pathol       Date:  2016-08-04       Impact factor: 1.271

6.  Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision.

Authors:  M L Darling; D N Smith; S C Lester; C Kaelin; D L Selland; C M Denison; P J DiPiro; D I Rose; E Rhei; J E Meyer
Journal:  AJR Am J Roentgenol       Date:  2000-11       Impact factor: 3.959

7.  Stereotactic vacuum-assisted breast biopsy in 2874 patients: a multicenter study.

Authors:  Ute Kettritz; Kerstin Rotter; Ingrid Schreer; Margarete Murauer; Rüdiger Schulz-Wendtland; Daniela Peter; Sylvia H Heywang-Köbrunner
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

8.  Ductal carcinoma in situ of the breast - Long term results from a twenty-year cohort.

Authors:  Michael Co; Ava Kwong
Journal:  Cancer Treat Res Commun       Date:  2017-10-26

9.  Stereotactic Vacuum-Assisted Breast Biopsy in Ductal Carcinoma in situ: Residual Microcalcifications and Intraoperative Findings.

Authors:  Benedict Krischer; Serafino Forte; Gad Singer; Rahel A Kubik-Huch; Cornelia Leo
Journal:  Breast Care (Basel)       Date:  2019-10-15       Impact factor: 2.860

10.  Tamoxifen Initiation After Ductal Carcinoma In Situ.

Authors:  Hazel B Nichols; Erin J A Bowles; Jessica Islam; Lawrence Madziwa; Til Stürmer; Diem-Thy Tran; Diana S M Buist
Journal:  Oncologist       Date:  2016-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.